The agency has been brought on board to work on the pharma company's Attention Deficit Hyperactivity Disorder (ADHD) partnership programme.
To begin with, the Resolute team will organise a meeting for UK physicians that will form part of the Continuing Medical Education scheme, which ensures that doctors' medical knowledge is up to date.
ADHD is a persistent pattern of inattention, hyperactivity and impulsivity. It is estimated to affect between three and five per cent of children. Symptoms are more likely to occur in group situations.
The UCB account will be headed up by Resolute associate director Kirsty Mearns with support from a team of four. Mearns has recently been promoted to the senior management team at the agency from her role as account director.
In her new role, Mearns will provide senior strategic counsel to her existing global clients, which include pharma firm Shire.
She will also lead a new account for Archimedes Pharma.